Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

Lenvatinib showed a median progression-free survival of 5.4 months in patients with advanced hepatocellular carcinoma (HCC) after progression on first-line atezolizumab plus bevacizumab (atezo-bev), surpassing the prespecified primary endpoint.
The objective response rate was 14.0%, with a high disease control rate of 82.0% and a median duration of response of 9.4 months, indicating durable clinical benefit.
The safety profile of lenvatinib was consistent with prior studies, with manageable toxicity including diarrhea, hypothyroidism, and anorexia; grade ≥3 adverse events occurred in 46% of patients.
This multicenter, prospective study provides the first robust clinical evidence supporting lenvatinib as a viable second-line treatment option post-atezo-bev failure in unresectable HCC.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Lenvatinib showed a median progression-free survival of 5.4 months in patients with advanced hepatocellular carcinoma (HCC) after progression on first-line atezolizumab plus bevacizumab (atezo-bev), surpassing the prespecified primary endpoint.
The objective response rate was 14.0%, with a high disease control rate of 82.0% and a median duration of response of 9.4 months, indicating durable clinical benefit.
The safety profile of lenvatinib was consistent with prior studies, with manageable toxicity including diarrhea, hypothyroidism, and anorexia; grade ≥3 adverse events occurred in 46% of patients.
This multicenter, prospective study provides the first robust clinical evidence supporting lenvatinib as a viable second-line treatment option post-atezo-bev failure in unresectable HCC.

Sign in free to continue reading